Table 1 Demographics and characteristics of patients infected with COVID-19

Characteristics

Age, years

40 (1–86)

45 (1–92)

Gender

 Male

31 (50.8)

33 (61.1)

 Female

30 (49.2)

21 (38.9)

Current smoking

4 (6.6)

6 (11.1)

Drinking

13 (21.3)

12 (22.2)

Exposure

 Wuhan residents come to Beijing

44 (72.1)

10 (18.5)

Comorbidity

 Diabetes

5 (8.2)

5 (9.3)

 Hypertension

12 (19.7)

13 (24.1)

 Cardiovascular disease

1 (1.6)

3 (5.6)

 Chronic obstructive pulmonary disease

5 (8.2)

1 (1.9)

Disease type on admission this hospital

 Mild

5 (8.2)

9 (16.7)

 Moderate

39 (63.9)

25 (46.3)

 Severe

14 (23.0)

15 (27.8)

 Critical

3 (4.9)

5 (9.3)

Signs and symptoms

 Highest temperature,  °C

  37.3–38.0

21 (34.4)

13 (24.1)

  38.1–39.0

34 (55.7)

25 (46.3)

  > 39.0

5 (8.2)

4 (7.4)

 Dyspnea

3 (4.9)

4 (7.4)

 Mild shortness of breath

7 (11.5)

12 (22.2)

 Cough

39 (63.9)

38 (70.4)

 Sputum production

27 (44.3)

22 (40.7)

 Fatigue

35 (57.4)

26 (48.1)

 Headache

21 (34.4)

6 (11.1)

 Chill

12 (19.7)

9 (16.7)

 Anorexia

8 (13.1)

6 (11.1)

 Nausea or vomiting

5 (8.2)

5 (9.3)

 Diarrhea

6 (9.8)

2 (3.7)

 Sore throat

10 (16.4)

8 (14.8

 Chest pain

1 (1.6)

0 (0)

 Systolic pressure < 90 or diastolic pressure ≤ 60, mmHg

5 (8.2)

6 (11.1)

 Respiratory rate > 30 breaths per min

2 (3.3)

4 (7.4)

Blood laboratory findings

 White blood cell count, ×10⁹/L

4.3 (3.5–5.1)

5.4 (4.1–7.0)

 Neutrophil count, ×10⁹/L

2.5 (2.1–3.5)

3.0 (2.1–4.6)

 Lymphocyte count, ×10⁹/L

1.0 (0.8–1.4)

1.3 (1.0–1.9)

 Monocyte count, ×10⁹/L

0.3 (0.2–0.4)

0.3 (0.2–0.4)

 NLR

2.6 (1.6–3.5)

2.3 (1.5–3.9)

 C-reactive protein, mg/L

12.0 (3.7–27.8)

21.6 (1.9–87.4)

 Hemoglobin, g/L

138.0 (127.0–150.5)

139.0 (127.8–147.0)

 Platelet count, ×10⁹/L

164.0 (135.0–219.5)

205.5 (149.8–263.6)

 Prothrombin time, s

12.0 (11.1–13.1)

12.2 (11.8–13.1)

 Potassium, mmol/L

3.8 (3.5–4.1)

3.8 (3.6–4.2)

 Sodium, mmol/L

139.0 (137.0–140.0)

138.5 (136.4–139.7)

 Serum Chlorine, mmol/L

102.0 (100.0–104.0)

102.3 (100.2–105.3)

 Serum urea nitrogen, mmol/L

4.3 (3.5–5.6)

4.3 (3.4–5.5)

 Creatinine, μmol/L

60.0 (47.0–69.5)

69.3 (51.6–80.1)

 Serum glucose, mmol/L

6.1 (5.5–6.9)

5.9 (5.2–7.7)

 Creatine kinase, U/L

93.0 (57.0–137.0)

89.4 (63.7–141)

 Alanine aminotransferase, U/L

19.0 (14.0–33.5)

23.7 (13.9–35.4)

 Albumin, g/L

44.0 (40.5–47.0)

41.1 (36.2–44.2)

 Multiple lung lobe or bilateral involvement

48 (78.7)

37 (68.5)

 With bacterial infection

8 (13.1)

6 (11.1)

Timeline after onset of illness, median (range)

 Days from illness onset to admission time

5 (0–23)

7 (0–21)

 Days from illness onset to dyspnea

3 (2–11)

7 (0–9)

 Days from illness onset to ICU admission

9 (2–14)

10 (4–14)

Treatment

 Antiviral therapy

34 (55.7)

36 (66.7)

 Antibiotic therapy

26 (42.6)

21 (38.9)

 Use of corticosteroid

2 (3.3)

3 (5.6)

 Oxygen support

20 (32.8)

24 (44.4)

  Nasal cannula

15 (24.6)

19 (35.2)

  Non-invasive ventilation

3 (4.9)

2 (3.7)

  Invasive mechanical ventilation

2 (3.3)

3 (5.6)

 Nebulization inhalation

52 (85.2)

49 (90.7)

Outcomes

 Dead

0 (0)

1 (1.9)

 Transfer to ICU

8 (13.1)

6 (11.1)

 Discharge

3 (4.9)

19 (35.2)

 Hospitalization

50 (82.0)

28 (51.9)